• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

第二剂 BNT162b2 新冠疫苗接种后反应原性与 SARS-CoV-2 抗体的相关性。

Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.

机构信息

Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.

Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.

出版信息

Vaccine. 2022 Mar 18;40(13):1924-1927. doi: 10.1016/j.vaccine.2022.02.052. Epub 2022 Feb 14.

DOI:10.1016/j.vaccine.2022.02.052
PMID:35183384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8841206/
Abstract

High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers.

摘要

高疫苗反应原性可能反映了更强的免疫反应，但针对 2019 年冠状病毒病（COVID-19）疫苗的流行病学证据很少且不一致。我们观察到，两剂 BNT162b2 疫苗接种后出现≥38℃的发热与更高的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突 IgG 滴度相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276c/8841206/effcaf163cb0/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276c/8841206/effcaf163cb0/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276c/8841206/effcaf163cb0/gr1_lrg.jpg

相似文献

1
Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine.第二剂 BNT162b2 新冠疫苗接种后反应原性与 SARS-CoV-2 抗体的相关性。
Vaccine. 2022 Mar 18;40(13):1924-1927. doi: 10.1016/j.vaccine.2022.02.052. Epub 2022 Feb 14.
2
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.BNT162b2 和 mRNA-1273 新冠疫苗作为两剂 ChAdOx1 nCoV-19 或 BNT162b2 疫苗后的第四剂加强针，以及一剂 BNT162b2 疫苗后的第三剂加强针的安全性、免疫原性和反应原性：一项多中心、盲法、2 期、随机试验。
Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi: 10.1016/S1473-3099(22)00271-7. Epub 2022 May 9.
3
Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare personnel.BNT162b2 疫苗第三剂对医护人员定量 SARS-CoV-2 刺突 1-2 IgG 抗体滴度的影响。
PLoS One. 2022 Mar 2;17(3):e0263942. doi: 10.1371/journal.pone.0263942. eCollection 2022.
4
Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.接种 BNT162b2 疫苗后医护人员抗严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突蛋白抗体效价和中和活性的相关因素。
PLoS One. 2022 Jun 10;17(6):e0269917. doi: 10.1371/journal.pone.0269917. eCollection 2022.
5
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.预充间隔对同源和异源 COVID-19 疫苗接种方案的反应原性、免疫反应峰值和消退的影响：Com-COV 的探索性分析，一项随机对照试验。
Lancet Respir Med. 2022 Nov;10(11):1049-1060. doi: 10.1016/S2213-2600(22)00163-1. Epub 2022 Jun 9.
6
A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects.一剂 BNT162b2 信使 RNA 疫苗可诱导 SARS-CoV-2 初治和恢复期 COVID-19 受试者的气道免疫。
Clin Infect Dis. 2022 Dec 19;75(12):2053-2059. doi: 10.1093/cid/ciac378.
7
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.维持性透析患者接种 SARS-CoV-2 疫苗后 6 个月的血清学反应。
Clin J Am Soc Nephrol. 2022 Mar;17(3):403-413. doi: 10.2215/CJN.12250921. Epub 2022 Feb 10.
8
Dyslipidemia and SARS-CoV-2 spike antibody titres after the second and third doses of the BNT162b2 vaccine among healthcare workers in Japan.在日本医护人员中，BNT162b2 疫苗第二剂和第三剂接种后血脂异常和 SARS-CoV-2 刺突抗体滴度。
Diabetes Metab Res Rev. 2023 Mar;39(3):e3606. doi: 10.1002/dmrr.3606. Epub 2022 Dec 29.
9
Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).老年人 HIV 感染者（PWH）接种 COVID-19 疫苗后对 SARS-CoV-2 刺突蛋白免疫原性的长期定量评估（QUASI）。
BMC Infect Dis. 2022 Sep 21;22(1):744. doi: 10.1186/s12879-022-07737-0.
10
Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.接种 BNT162b2 mRNA COVID-19 疫苗的孕妇的短期结局。
Ultrasound Obstet Gynecol. 2021 Sep;58(3):450-456. doi: 10.1002/uog.23729. Epub 2021 Aug 9.

引用本文的文献

1
Incidence of narcolepsy symptoms after taking COVID-19 vaccines: a Jordanian cross-sectional study.接种新冠疫苗后发作性睡病症状的发生率：一项约旦横断面研究。
Clin Exp Vaccine Res. 2024 Jul;13(3):218-224. doi: 10.7774/cevr.2024.13.3.218. Epub 2024 Jul 31.
2
The Relationship between Immunogenicity and Reactogenicity of Seasonal Influenza Vaccine Using Different Delivery Methods.使用不同递送方法的季节性流感疫苗的免疫原性与反应原性之间的关系
Vaccines (Basel). 2024 Jul 21;12(7):809. doi: 10.3390/vaccines12070809.
3
Association between Reactogenicity and Immunogenicity in a Vaccinated Cohort with Two mRNA SARS-CoV-2 Vaccines at a High-Complexity Reference Hospital: A Analysis on Immunology Aspects of a Prospective Cohort Study.

本文引用的文献

1
Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.年龄相关的对 BNT162b2 疫苗诱导的针对 SARS-CoV-2 阿尔法和贝塔变异株的中和作用的降低。
Microbiol Spectr. 2021 Dec 22;9(3):e0056121. doi: 10.1128/Spectrum.00561-21. Epub 2021 Dec 1.
2
Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?第二剂 BNT162b2 疫苗接种后的不良反应是否能预测健康日本受试者的刺突 IgG 抗体水平？
PLoS One. 2021 Sep 20;16(9):e0257668. doi: 10.1371/journal.pone.0257668. eCollection 2021.
3
在一家高复杂性参考医院接种两种mRNA新冠疫苗的队列中反应原性与免疫原性之间的关联：一项前瞻性队列研究的免疫学方面分析
Vaccines (Basel). 2024 Jun 17;12(6):665. doi: 10.3390/vaccines12060665.
4
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity.对前新冠病毒疫苗候选物CVnCoV的先天反应及其与反应原性和适应性免疫原性的关系。
Vaccines (Basel). 2024 Apr 6;12(4):388. doi: 10.3390/vaccines12040388.
5
Association between sleep duration and antibody acquisition after mRNA vaccination against SARS-CoV-2.mRNA 疫苗接种后睡眠时长与 SARS-CoV-2 抗体获得的相关性。
Front Immunol. 2023 Dec 11;14:1242302. doi: 10.3389/fimmu.2023.1242302. eCollection 2023.
6
T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis.新冠病毒加强疫苗在接受血液透析治疗的日本慢性肾脏病患者中诱导的T细胞反应和抗体产生
Vaccines (Basel). 2023 Mar 14;11(3):653. doi: 10.3390/vaccines11030653.
7
Associations of Polymorphisms with Anti-SARS-CoV-2 Spike and Neutralizing Antibody Titers in Japanese Rheumatoid Arthritis Patients Vaccinated with BNT162b2.接种BNT162b2疫苗的日本类风湿性关节炎患者中多态性与抗SARS-CoV-2刺突蛋白及中和抗体滴度的关联
Vaccines (Basel). 2023 Feb 9;11(2):404. doi: 10.3390/vaccines11020404.
8
Comparison of risk factors for SARS-CoV-2 infection among healthcare workers during Omicron and Delta dominance periods in Japan.比较日本奥密克戎和德尔塔变异株流行期间医护人员感染 SARS-CoV-2 的危险因素。
J Hosp Infect. 2023 Apr;134:97-107. doi: 10.1016/j.jhin.2023.01.018. Epub 2023 Feb 16.
9
Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study.mRNA-1273接种者中反应原性对抗SARS-CoV-2抗体反应的预测价值：一项多中心前瞻性队列研究
Vaccines (Basel). 2023 Jan 3;11(1):120. doi: 10.3390/vaccines11010120.
10
Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers.在韩国医护人员中，ChAdOx1 nCOV-19 冠状病毒病 2019 疫苗的反应原性和免疫原性。
Yonsei Med J. 2022 Dec;63(12):1078-1087. doi: 10.3349/ymj.2022.0298.
Can reactogenicity predict immunogenicity after COVID-19 vaccination?
接种 COVID-19 疫苗后，反应原性能否预测免疫原性？
Korean J Intern Med. 2021 Nov;36(6):1486-1491. doi: 10.3904/kjim.2021.210. Epub 2021 May 28.
4
COVID-19 vaccines: modes of immune activation and future challenges.COVID-19 疫苗：免疫激活模式和未来挑战。
Nat Rev Immunol. 2021 Apr;21(4):195-197. doi: 10.1038/s41577-021-00526-x.
5
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
6
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
7
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
8
The how's and what's of vaccine reactogenicity.疫苗反应原性的情况与内容。
NPJ Vaccines. 2019 Sep 24;4:39. doi: 10.1038/s41541-019-0132-6. eCollection 2019.
9
Fever and the thermal regulation of immunity: the immune system feels the heat.发热与免疫的体温调节：免疫系统能感知热度。
Nat Rev Immunol. 2015 Jun;15(6):335-49. doi: 10.1038/nri3843. Epub 2015 May 15.
10
Cytokines and fever. Mechanisms and sites of action.细胞因子与发热。作用机制及作用部位。
Ann N Y Acad Sci. 1998 Sep 29;856:83-89. doi: 10.1111/j.1749-6632.1998.tb08316.x.